Clinical trials: Thrombus
Pulmonary Thromboembolisms, Anticoagulants; Increased
Personalized Anticoagulant Therapy for Pulmonary Thromboembolism
The goal of this prospective observational study is to explore the influencing factors of the efficacy and safety of anticoagulant therapy for pulmonary thromboembolism in special populations with older age, renal insufficiency…
- Trial name
- NCT06341231
- Where
- China
- Volunteers
- 4,700 people
- Sponsor
- Xiangya Hospital of Central South University
Thromboembolism
Balancing of Patients Treated by Vitamin K Antagonists (VKAS) in General Medicine
Despite the rise in prescriptions for direct oral anticoagulants,Vitamin K antagonists(VKA) remains the most prescribed treatment for treating and preventing long-term thromboembolic events.
- Trial name
- VKA (NCT03914053)
- Where
- France
- Volunteers
- 3,387 people
- Sponsor
- University Hospital, Montpellier
Thrombosis, Cardiovascular Diseases
A Phase I SAD/MAD and Liver Effect Study of Vitalangio in Venous Thromboembolism Patients .
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a new drug, Vitalangio1, in healthy male and female volunteers aged 18 to 55 years old.
- Trial name
- NCT07618351
- Testing
- Experimental: Food effect group, Active Comparator: Multiple dose group
- Where
- China
- Volunteers
- 627 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
Thrombosis
Safety and Tolerability Study of BMS-986177 in Healthy Subjects
The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of BMS-986177 in healthy subjects
- Trial name
- NCT02608970
- Testing
- BMS-986177
- Where
- Belgium
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Venous Thromboembolism
Non Interventional Study of the Validation of the Ottawa Score in Cancer Patients With Venous Thromboembolism (VTE)
The purpose of this study is to validate the Ottawa score (risk of thromboembolic recurrences) in cancer patients with thromboembolic disease treated with tinzaparin (Innohep®)
- Trial name
- PREDICARE (NCT03099031)
- Testing
- Tinzaparin
- Where
- France
- Volunteers
- 420 people
- Sponsor
- LEO Pharma
Superficial Thrombophlebitis, Upper Extremity Superficial Thrombophlebitis
Management of Superficial Thrombophlebitis
The purpose of this study is to test the hypothesis that Fragmin (dalteparin sodium) subcutaneously once daily for 7 days is more effective than Ibuprofen given orally three times daily for 7 days for the treatment of superficial…
- Conditions
- Superficial Thrombophlebitis, Upper Extremity Superficial Thrombophlebitis, Lower Extremity Superficial Thrombophlebitis
- Trial name
- NCT00264381
- Testing
- Dalteparin sodium injection
- Where
- 2 sites in United States
- Volunteers
- 72 people
- Sponsor
- University of Oklahoma
Pulmonary Embolism
Evaluating the Safety and Efficacy of the Indigo® Aspiration System in Acute Pulmonary Embolism
To determine the safety and efficacy of the Indigo Aspiration System for aspiration mechanical thrombectomy in patients with acute pulmonary embolism (PE)
- Trial name
- EXTRACT-PE (NCT03218566)
- Testing
- Indigo Aspiration System
- Where
- 22 sites in United States
- Volunteers
- 119 people
- Sponsor
- Penumbra Inc.
Deep Vein Thrombosis
Selective D-Dimer Testing Compared With Uniform D-Dimer Testing in the Diagnosis of Deep Vein Thrombosis (SELECT)
The purpose of this study is to compare two diagnostic interventions to improve the way D-dimer blood testing (MDA D-dimer) is used to diagnose first time symptomatic deep vein thrombosis.
- Trial name
- SELECT (NCT00157677)
- Testing
- D-dimer testing
- Where
- 5 sites in Canada
- Volunteers
- 1,727 people
- Sponsor
- McMaster University
Cerebral Vein Thrombosis, Deep Vein Thrombosis
Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy
This randomized phase III trial studies the best dose of apixaban and how well it works in preventing secondary cancer related venous thrombosis in cancer patients who have completed anticoagulation therapy.
- Conditions
- Cerebral Vein Thrombosis, Deep Vein Thrombosis, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT03080883
- Testing
- Apixaban
- Where
- 32 sites in United States
- Volunteers
- 370 people
- Sponsor
- Academic and Community Cancer Research United
Venous Thromboembolism
Efficacy of ICU-VTE Scale in ICU Patients
Venous thromboembolism (VTE) is a common cause of morbidity and mortality among critically ill patients. No uniform standard model of VTE risk for critically ill patients was formatted by now. In 2020, Viarasilpa et al.
- Trial name
- NCT05487066
- Where
- China
- Volunteers
- 269 people
- Sponsor
- Lijuan Zhang
Macular Degeneration, Diabetic Retinopathy
Patient Comfort Following Intravitreal Injections Using Iheezo Versus Standard Anesthesia
Prospective comparative clinical study. One hundred eyes of 50 patients were included. All patients received bilateral same-day intravitreal injections, with Iheezo administered to only one randomly selected eye and standard…
- Conditions
- Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion (RVO)
- Trial name
- NCT07779356
- Testing
- Iheezo, Lidocaine pledget
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Retina Consultants of Delmarva
Mitral Regurgitation
STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients With an Indication for Oral Anticoagulant
Mitral regurgitation (MR) is the most common valvular heart disease, affecting approximately 24.2 million people worldwide (with a higher prevalence in older age groups).
- Trial name
- STAR-TEER Ⅰ (NCT06901466)
- Testing
- Experimental: Rivaroxaban monotherapy, Active Comparator: Rivaroxaban+Clopidogrel
- Where
- China
- Volunteers
- 880 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Venous Thrombosis, Pulmonary Embolism
Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness
The purpose of this study is to learn if apixaban can prevent blood clots in the leg (deep vein thrombosis [DVT]) and lung (pulmonary embolism [PE]) that sometimes occur within patients hospitalized for acute medical illness, and…
- Trial name
- ADOPT (NCT00457002)
- Testing
- Apixaban, Enoxaparin
- Where
- 296 sites in United States, Argentina and 33 more
- Volunteers
- 6,758 people
- Sponsor
- Bristol-Myers Squibb
Venous Thromboembolism
Chinese Community Inpatient Thromboembolism
This study is a multicenter cross-sectional study conducted at 20 centers. Data of existing inpatients in 20 community hospitals were collected.
- Trial name
- COMET (NCT06168331)
- Where
- 2 sites in China
- Volunteers
- 1,152 people
- Sponsor
- RenJi Hospital
Cardiopathy, Chagas Disease
Outcomes of an Anticoagulation Clinic in an University Hospital
A clinical trial designed to compare the oral anticoagulation control obtained by an anticoagulation clinic and the usual medical care in Chagas and Non-Chagas disease patients.
- Conditions
- Cardiopathy, Chagas Disease, Hemorrhage, Thrombosis
- Trial name
- NCT01006486
- Testing
- Anticoagulation clinic, Standard anticoagulation care
- Where
- Brazil
- Volunteers
- 280 people
- Sponsor
- Federal University of Minas Gerais
Von Willebrand Disease, Type 1
Evaluation of Bleeding Score in Egyptian Patients With vWD Type I and Correlate it With Laboratory Parameters
Applying the ISTH-BAT questionnaire on Egyptian patients with type I VWD aiming to correlate the BS with the laboratory findings
- Trial name
- NCT03915873
- Testing
- The von Willebrand Antigen level
- Volunteers
- 20 people
- Sponsor
- Assiut University
Raynaud's Phenomenon Secondary to Systemic Sclerosis
Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)
This is a Phase 3, multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of iloprost on the frequency of and relief from symptomatic digital ischemic episodes in subjects with…
- Trial name
- NCT04040322
- Testing
- Iloprost Injection, for intravenous use
- Where
- 30 sites in United States
- Volunteers
- 198 people
- Sponsor
- Civi Biopharma, Inc.
Pulmonary Embolism
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study
This is a multicenter, randomized, open-label, assessor-blind, event-driven, non-inferiority program for efficacy with a study treatment duration of 3, 6 or 12 months in patients with confirmed acute symptomatic pulmonary…
- Trial name
- NCT00439777
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin overlapping with and followed by VKA
- Where
- 305 sites in United States, Andorra and 37 more
- Volunteers
- 4,833 people
- Sponsor
- Bayer
Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
Tislelizumab Combined With IMRT Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT
Due to the biological characteristics and liver anatomical characteristics of liver cancer, liver cancer cells easily invade the vascular system, especially the portal venous system, forming portal vein tumor thrombus (PVTT) …
- Trial name
- NCT04850157
- Testing
- Tislelizumab, IMRT
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Zhongshan Hospital
Healthy Volunteers, Endotoxemia
Defibrotide in the Human Endotoxemia Model --- an Exploratory Trial Investigating the Effects and the Mechanisms of Defibrotide
Defibrotide is an anti-inflammatory and anti-coagulatory agent approved for treatment of veno-occlusive disease. Although it has been in clinical use for almost 30 years, the exact mechanism of action has never been fully…
- Trial name
- LPS_DF (NCT02876601)
- Testing
- Defibrotide, Lipopolysaccharide
- Where
- Austria
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bernd Jilma